New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Royalty Pharma PLC

RPRX

Healthcare Biotechnology

Royalty Pharma PLC’s revenue for fiscal 2025 (year ended December 2025) was $2.4 billion, up 5.06% from fiscal 2024.

Revenue
+13.3%
EPS
−61.2%
Free cash flow
n/m
Total debt
−4.00%

Quarter to September 2026, against a year earlier

68.45 0.73 +1.08%

After hours trading: 69.00, up 0.80%, last trade 4:29pm Eastern.

Market cap
$38.9B
P/E
47.2×
Fwd P/E FY26e
35.9×
Dividend yield
1.37%
F-score
5/9
ROIC
5.24%
Net debt / EBITDA
5.2×
Payout ratio
0.7×

Royalty Pharma PLC (RPRX) Business Profile

Updated · Covers results through FY2025 · How this is made

What it does

Royalty Pharma buys rights to payments tied to sales of medicines. Rather than developing, manufacturing or selling most of the medicines itself, it provides capital to the organizations that own royalty rights or are developing therapies. In return, it receives a share of the sales of specified products, along with milestones or other contractual payments in some transactions.

Its partners range from academic institutions, research hospitals and nonprofits to biotechnology and pharmaceutical companies. An institution that helped discover a therapy may sell an existing royalty to Royalty Pharma. A drug developer may instead create a new royalty in exchange for funding, while retaining responsibility for developing and selling the medicine.

The company invests across therapeutic areas and treatment types, focusing on approved medicines and development-stage candidates with proof-of-concept data. Its portfolio at the end of 2025 included royalties on more than 35 commercial products and 20 development-stage product candidates. The marketed products included Vertex’s Trikafta and Alyftrek, GSK’s Trelegy and Roche’s Evrysdi.

Royalty Pharma’s predecessor was founded in 1996. The company’s principal executive offices are in New York, and Pablo Legorreta is its chief executive officer.

How it makes money

Royalty Pharma earns payments under contracts linked primarily to medicine sales. Existing third-party royalties give it a contractual right to a percentage of sales made by a licensee. Synthetic royalties are newly created rights to a percentage of a developer’s or marketer’s sales, provided in exchange for funding. Contract terms differ by product: rates can change at specified sales thresholds, and rights can cover particular markets or periods.

For example, the Trelegy royalty has tiers based on annual sales. The Voranigo royalty applies to U.S. sales, while some other agreements cover worldwide sales. Royalty Pharma can also provide debt, equity, or launch and development capital as part of a transaction, in exchange for fixed payments or other contractual rights.

Portfolio Receipts are the company’s measure of cash generated by its portfolio. They include sales-based Royalty Receipts and milestones and other contractual receipts, net of contractual payments to legacy non-controlling interests. Sales-based receipts recur as the underlying products are sold; milestones and other contractual receipts can be more variable.

Portfolio Receipts were $3.3 billion in 2025 and $890 million in the third quarter of 2026.

For FY2025, income from financial royalty assets was $2.3 billion, while other royalty income and revenues were $117.0 million. Most acquired royalties are accounted for as financial assets using an effective interest method based on expected lifetime cash flows. Changes in those expectations can produce non-cash provisions or reversals, so reported royalty income is not the same measure as cash royalty receipts.

Product or service Revenue, FY2025 Share Change on the year
Income from financial royalty assets $2.3 billion 95.1% 5.20%
Other royalty income and revenues $117.0 million 4.92% 2.53%

Customers and how it sells

Royalty Pharma’s counterparties include the institutions and companies that sell existing royalties, as well as developers seeking funding in exchange for newly created royalties. It collaborates with academic institutions, research hospitals, nonprofits, biotechnology companies and global pharmaceutical companies. The companies marketing the underlying medicines make sales to patients and other purchasers; Royalty Pharma receives payments under its contracts rather than selling those medicines directly.

Vertex’s cystic fibrosis franchise was the company’s largest marketed royalty in 2025. Other medicines in its portfolio are marketed by companies including GSK, Biogen, Roche, Pfizer and Johnson & Johnson. In 2025, no individual product accounted for more than 26% of Portfolio Receipts.

Royalty terms determine geographic exposure. For example, the Voranigo royalty applies to U.S. sales, while the Imdelltra royalty covers worldwide net sales excluding China. Trelegy’s arrangement has different dates for the return of portions of U.S. and non-U.S. royalties to GSK.

Royalty Pharma has expanded its team in Asia to pursue opportunities associated with licensing activity. Its principal executive offices are in New York.

Suppliers and costs

Royalty Pharma’s business depends on obtaining royalty rights and funding opportunities from owners and developers of therapies. It does not bear the fixed research and development, manufacturing and commercial infrastructure costs associated with the products on which it acquires royalties. The marketers of those products are outside its control and remain responsible for their commercialization.

The company’s principal cash operating expenses, apart from research and development funding commitments, include interest, employee personnel costs, rent, and legal and professional fees. It had 100 employees as of December 31, 2025. Following its acquisition of its former external manager in May 2025, it no longer pays management fees.

Royalty acquisitions and funding commitments require capital. In 2025, the company deployed $2.6 billion of cash to acquire royalties, milestones and other contractual receipts. The par value of its outstanding borrowings was $9.2 billion as of December 31, 2025. It has historically funded investments through operating cash flows, equity contributions and debt.

From revenue to operating income, FY2025
  1. Revenue$2.4B
  2. Research and development−$452.0M
  3. Selling, general and administrative−$573.5M
  4. Other operating costs−−$206.8M
  5. Operating income$1.6B

Competitive position

Royalty Pharma competes with other buyers for a limited number of royalty acquisition opportunities. Potential buyers include pharmaceutical companies marketing the underlying products, investment vehicles, financial institutions, sovereign wealth and pension funds, and other pools of capital. Some may be larger or better capitalized. Drug developers can also choose equity, debt, convertible debt or licensing arrangements instead of royalty funding.

The medicines underlying Royalty Pharma’s contracts compete with other treatments, including generics and biosimilars. Their sales can be affected by price, reimbursement, safety, effectiveness, marketing support and product exclusivity.

Royalty Pharma estimates that it executed approximately 48% of royalty transactions by value from 2020 through 2025. It estimates that its nearest competitor had a 14% share over the same period, but does not name that competitor. The available material names no company as a competing royalty buyer.

Our reading: Royalty Pharma’s transaction scale is a meaningful competitive advantage in pursuing large deals, although other buyers can have greater financial resources. Our reading: Its specialist investment process and industry relationships may help it evaluate opportunities, but their strength is harder to establish independently from the available evidence.

Growth opportunities

Royalty Pharma seeks growth both from sales of medicines already in its portfolio and from acquiring additional royalties. New investments can also supplement or offset declines in royalties on products that lose market exclusivity. The company targets approved therapies and development-stage candidates with proof-of-concept data, using existing royalties, synthetic royalties and other funding structures.

Royalty Pharma estimates that the biopharmaceutical royalty market reached $10.0 billion in transaction value in 2025. It sees funding needs across academia, nonprofits and drug companies as a source of potential transactions. It also identifies licensing activity involving Chinese biotechnology companies as a long-term opportunity.

In 2026, the company announced $1 billion of research and development co-funding deals, including $500 million with J&J and $500 million with Teva. By the third quarter of 2026, it had deployed $1.6 billion of capital that year. Royalty receipts grew by 12% in the first nine months of 2026.

Royalty Pharma expects 2026 Portfolio Receipts of $3.5 billion to $3.55 billion. Its expectation is based on the portfolio it held at the time and excludes benefits from future royalty acquisitions.

Revenue by fiscal year
  1. $2.3BFY2021
  2. $2.2BFY2022
  3. $2.4BFY2023
  4. $2.3BFY2024
  5. $2.4BFY2025

Structural risks

  • Product sales and competition: Royalty payments depend on sales of underlying medicines. Generics, biosimilars, alternative treatments, pricing and reimbursement policies, or a product’s withdrawal can reduce payments or lead to asset impairment charges.
  • Development and approval: Development-stage candidates may not succeed in clinical trials or obtain regulatory approval. Royalty Pharma reported that the pelacarsen outcomes trial was unsuccessful; it structured the investment to provide protection.
  • Concentration and contract terms: Vertex’s cystic fibrosis franchise was the largest marketed royalty in 2025. Royalty Pharma and Vertex have different views on whether a component of Alyftrek is royalty-bearing, affecting the applicable blended royalty.
  • Acquisition opportunities: Competition for a limited number of suitable royalties may prevent the company from investing available capital in acceptable assets. Developers can also choose other forms of financing.
  • Debt and cash flow: Higher borrowing rates can increase costs, while debt covenants can constrain business objectives. Royalty Pharma’s ability to service debt and meet obligations depends on future operating performance and cash flow.

Bottom line

Our reading

Royalty Pharma is a financing business whose cash receipts depend on medicines sold by other companies, not a conventional drug manufacturer. Its portfolio and transaction scale support continued investment, but product competition, development setbacks and the availability of new royalty deals shape future receipts. Debt adds another claim on the cash generated by that portfolio.